Estonia

Key Insights

1
No psychedelic therapy is approved in Estonia; access is limited to licensed medical use and scientific handling under narcotics law, with psychotropics tightly controlled. ([riigiteataja.ee](https://www.riigiteataja.ee/en/compare_original/529052023005?utm_source=openai))
2
The database shows 4 trials, 1 active, and 1 research organisation; esketamine and placebo are the only compounds recorded. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02417064?utm_source=openai))
3
Estonia has hosted esketamine studies in Tallinn, Pärnu and Tartu, giving it a visible footprint in international depression research. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02417064?utm_source=openai))
4
Momentum is concentrated at the University of Tartu-linked ecosystem and Janssen-led esketamine programmes, which still anchor Estonia's psychedelic-relevant clinical activity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/32299306/?utm_source=openai))

Medical Only (Private)

Reimbursed Care Access

Estonia maintains a restrictive controlled‑substances regime: classic psychedelics (psilocybin, MDMA, DMT, mescaline, 2C‑X, 5‑MeO‑DMT, ibogaine, ayahuasca preparations) are scheduled and have no routine medical reimbursement outside authorised clinical research. One exception in clinical psychiatric care is esketamine (Spravato) which holds an EU marketing authorisation and is registered for use — however, its use in Estonia is delivered through medical prescription/clinic pathways and is not generally available as a routinely reimbursed, publicly funded antidepressant therapy. Ketamine itself remains a licensed anaesthetic and is used off‑label in some private psychiatric settings for treatment‑resistant depression, typically without public reimbursement for the psychiatric indication.

Full guide →